Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2016
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms HARUKAS
- 07 Jun 2017 Biomarkers information updated
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.